Angiotensin II Receptor Blockers: How the Drug Class Works
Angiotensin II receptor blockers, or ARBs, are prescription medicines that occupy the AT1 receptor so angiotensin II, an eight amino acid peptide, cannot signal through it. Blocking AT1 lowers vasoconstriction and aldosterone release within the renin-angiotensin-aldosterone system. Unlike ACE inhibitors, ARBs do not block the enzyme that degrades bradykinin, which is why the two classes differ in cough profile. Labels describe uses in hypertension and related conditions and carry class warnings. A prescriber decides whether and which medicine is used.
Angiotensin II receptor blockers (ARBs) are a class of prescription medicines that bind the angiotensin II type 1 receptor (AT1) and prevent angiotensin II from activating it. Generic members of the class include losartan, valsartan, candesartan, telmisartan, irbesartan and olmesartan. This page explains the mechanism at the receptor level, how that mechanism sits inside the renin-angiotensin-aldosterone system (RAAS), and how the class differs from angiotensin converting enzyme (ACE) inhibitors. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, symptom or health decision. Whether a medicine in this class is appropriate, and which one, is a decision made by a prescribing clinician, not by a web page.
The peptide at the centre: angiotensin II
Angiotensin II is an eight amino acid peptide hormone generated by a cascade: the kidney releases renin, renin cleaves angiotensinogen to angiotensin I, and ACE converts angiotensin I to angiotensin II. The peptide itself is covered in depth on the dedicated physiology pages for angiotensin II, angiotensin and renin; this guide concentrates on what happens pharmacologically when its main receptor is blocked.
A 2014 review of renin-angiotensin system blocking drugs described the cascade as a sequence of enzymatic steps that can be interrupted at several points, including renin activity, ACE activity and the receptor itself, and grouped the available drug classes by where in that sequence they act (https://pubmed.ncbi.nlm.nih.gov/24038019/). A 2020 review of RAAS targeting in fibrosis similarly described angiotensin II signalling as extending beyond blood pressure control into tissue remodelling pathways (https://pubmed.ncbi.nlm.nih.gov/32422329/).
The AT1 receptor and what blocking it does
Angiotensin II signals through at least two receptor subtypes, AT1 and AT2. Most of the classical pressor and sodium-retaining actions of the peptide are attributed to AT1. ARBs are selective antagonists at AT1, so they occupy the receptor and leave angiotensin II unable to trigger its downstream signalling there, regardless of how much peptide is circulating.
Blocking AT1 has several consequences that follow logically from the receptor's normal roles:
- Vascular tone. AT1 activation on vascular smooth muscle produces vasoconstriction; antagonism of the receptor removes that stimulus.
- Aldosterone release. AT1 activation in the adrenal cortex drives aldosterone secretion, which promotes sodium and water retention.
- Renal handling of sodium. A 2002 review on the kidney and hypertension discussed the central role of renal sodium handling and the renin-angiotensin system in blood pressure regulation (https://pubmed.ncbi.nlm.nih.gov/11982815/).
- Tissue remodelling. The 2020 fibrosis review reported that angiotensin II signalling contributes to profibrotic pathways in multiple organs and that RAAS blockade has been examined as an antifibrotic strategy (https://pubmed.ncbi.nlm.nih.gov/32422329/).
Because the blockade happens at the receptor rather than at an enzyme upstream, circulating angiotensin II concentrations are not reduced by ARBs; the peptide is simply unable to act at AT1. Some of it remains available to stimulate AT2 and other receptor subtypes, a pharmacological distinction that researchers have discussed when comparing RAAS blocking strategies (https://pubmed.ncbi.nlm.nih.gov/24038019/).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeARBs versus ACE inhibitors: where the two classes diverge
Both classes interrupt the same hormonal axis, but at different points.
| Feature | ACE inhibitors | ARBs |
|---|---|---|
| Target | Angiotensin converting enzyme | AT1 receptor |
| Effect on angiotensin II formation | Reduces conversion of angiotensin I to angiotensin II by ACE | No direct effect on formation |
| Effect on AT2 signalling | Less angiotensin II available for any receptor | Angiotensin II remains available to non-AT1 receptors |
| Bradykinin metabolism | ACE also degrades bradykinin, so inhibition allows bradykinin accumulation | No enzyme inhibition, so bradykinin degradation is unaffected |
| Alternative angiotensin II pathways | Non-ACE enzymes can still generate angiotensin II | Receptor is blocked irrespective of how angiotensin II was generated |
The bradykinin point is the one that most often explains differences in tolerability discussion. ACE is not an angiotensin-specific enzyme; it is a peptidase that also breaks down bradykinin, a vasodilator peptide. Inhibiting ACE therefore slows bradykinin degradation, and the resulting accumulation is the mechanism conventionally invoked for the dry cough and for angioedema associated with ACE inhibitors. ARBs do not inhibit that enzyme, so bradykinin metabolism proceeds normally and the cough mechanism does not apply in the same way. The dedicated guide on bradykinin and ACE inhibitors covers that peptide in detail. A 2014 review of RAS blocking drugs set out these mechanistic differences between enzyme inhibition and receptor antagonism (https://pubmed.ncbi.nlm.nih.gov/24038019/).
Neither description ranks one class above the other for any individual. Which class suits a given person depends on clinical factors a prescriber assesses.
Aldosterone breakthrough
RAAS blockade does not always suppress aldosterone indefinitely. A 2022 pharmacological review described aldosterone breakthrough, the phenomenon in which aldosterone concentrations return toward or above baseline during continued treatment with RAAS inhibitors, and examined proposed mechanisms for it (https://pubmed.ncbi.nlm.nih.gov/35422512/). The same review discussed why this matters pharmacologically, given aldosterone's roles beyond sodium retention (https://pubmed.ncbi.nlm.nih.gov/35422512/). This is a mechanism-level observation reported in the literature, not a reason for any reader to change anything.
Tracking research? Log entries with dates, lots and notes: records, never plans.
Get the appUses described in labels and reviews
Approved indications vary by individual generic drug and by regulatory jurisdiction, and the authoritative source for any one product is its own approved label. At class level, labels describe use in hypertension, and for particular agents in heart failure, after myocardial infarction, and in diabetic kidney disease. A 2002 review on kidney and hypertension discussed the kidney as both a cause and a target of hypertension and the rationale for RAAS-directed treatment in that setting (https://pubmed.ncbi.nlm.nih.gov/11982815/).
Combination products
Valsartan appears in a fixed combination with sacubitril, a neprilysin inhibitor. A 2017 review described that combination as acting on natriuretic peptide handling in addition to AT1 blockade, and discussed effects beyond natriuretic peptides attributable to neprilysin inhibition (https://pubmed.ncbi.nlm.nih.gov/28689178/).
Metabolic observations
A 2024 comprehensive review examined telmisartan and components of the metabolic syndrome, summarising reported effects on blood pressure alongside lipid and glucose-related parameters and attributing part of the interest to partial PPAR-gamma activity (https://pubmed.ncbi.nlm.nih.gov/38228033/). A 2016 review of pharmacological modulators of endoplasmic reticulum stress in metabolic disease included RAAS-directed agents among compounds studied for effects on ER stress pathways (https://pubmed.ncbi.nlm.nih.gov/26840310/). A 2014 review of adiponectin effects on the kidney discussed adiponectin signalling in renal tissue and its intersection with renal protective strategies (https://pubmed.ncbi.nlm.nih.gov/24417947/). These are research-level observations in reviews and are not themselves approved indications.
Uric acid
A 2015 review on gout and hypertension discussed the relationship between urate handling and antihypertensive drug classes, including the uricosuric property associated with losartan (https://pubmed.ncbi.nlm.nih.gov/26118024/).
Investigational and off-label areas in the literature
A 2025 scoping review assessed candesartan for migraine headache and summarised the published studies on that use (https://pubmed.ncbi.nlm.nih.gov/40571531/). A 2009 review of the pathophysiological basis of migraine prophylaxis placed candidate prophylactic mechanisms, including vascular and neuronal targets, in a broader framework (https://pubmed.ncbi.nlm.nih.gov/19654035/). Separately, a 2024 experimental eye research paper described a two-phase mechanism in the treatment of corneal stromal fibrosis with topical losartan in a laboratory model (https://pubmed.ncbi.nlm.nih.gov/38570181/). Research contexts like these do not establish approved uses, and the prescribing clinician remains the decision maker.
Class Adverse Effects: What Studies Report
Adverse effect profiles are specific to each approved product label; the points below are class-level themes described in labels and in the cited reviews.
- Hypotension and dizziness. Because the class reduces angiotensin II mediated vasoconstriction, labels describe symptomatic low blood pressure, particularly in volume-depleted states. A 2014 review of RAS blocking drugs discussed blood pressure lowering as the shared pharmacological consequence of the class (https://pubmed.ncbi.nlm.nih.gov/24038019/).
- Potassium elevation. Reduced aldosterone signalling can raise serum potassium; a 2022 review of aldosterone breakthrough described aldosterone's role in potassium handling during RAAS inhibition (https://pubmed.ncbi.nlm.nih.gov/35422512/).
- Renal function changes. Labels carry warnings about changes in renal function in susceptible individuals, including those with renal artery stenosis or volume depletion. A 2002 review on kidney and hypertension described the dependence of glomerular filtration on angiotensin II mediated efferent arteriolar tone (https://pubmed.ncbi.nlm.nih.gov/11982815/). Monitoring decisions belong to the prescribing clinician.
- Pregnancy. Labels for drugs acting on the renin-angiotensin system carry a boxed warning regarding use in pregnancy. The content and application of that warning are matters for the prescribing clinician and the approved label.
- Angioedema. Reported rarely with ARBs. Because ARBs do not inhibit ACE, the bradykinin accumulation mechanism associated with ACE inhibitors does not apply in the same way (https://pubmed.ncbi.nlm.nih.gov/24038019/).
No dosing information, titration schedule or combination strategy appears on this page. Those belong to the approved label and the prescribing clinician.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeWhat this class is not
ARBs are prescription medicines regulated as drugs. They are not supplements, not research chemicals in the sense used for unapproved peptides, and not interchangeable with one another by reader preference. Direct renin inhibitors, ACE inhibitors and mineralocorticoid receptor antagonists all act on the same axis at different points, and a 2014 review grouped these classes by their mechanistic position in the cascade (https://pubmed.ncbi.nlm.nih.gov/24038019/).
Every personal question about suitability, interactions, monitoring, pregnancy, kidney function or any change in treatment should be directed to the prescribing clinician.
References
- Renin-angiotensin system blocking drugs (Journal of Cardiovascular Pharmacology and Therapeutics, 2014)
- Kidney and hypertension (Kidney International Supplement, 2002)
- Aldosterone breakthrough from a pharmacological perspective (Hypertension Research, 2022)
- Targeting the renin-angiotensin-aldosterone system in fibrosis (Matrix Biology, 2020)
- Sacubitril/valsartan: beyond natriuretic peptides (Heart, 2017)
- Effects of telmisartan on metabolic syndrome components: a comprehensive review (Biomedicine & Pharmacotherapy, 2024)
- Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases (International Journal of Molecular Sciences, 2016)
- Adiponectin effects on the kidney (Best Practice & Research Clinical Endocrinology & Metabolism, 2014)
- Gout and hypertension (Likars'ka Sprava, 2015)
- Candesartan for Treatment of Migraine Headache: A Scoping Review (Clinical Therapeutics, 2025)
- Pathophysiological basis of migraine prophylaxis (Progress in Neurobiology, 2009)
- Two-phase mechanism in the treatment of corneal stromal fibrosis with topical losartan (Experimental Eye Research, 2024)
Frequently asked questions
What do angiotensin II receptor blockers do?▾
They occupy the AT1 receptor so angiotensin II, an eight amino acid peptide, cannot activate it. That removes the AT1-driven stimulus for vasoconstriction and aldosterone release. A 2014 review of renin-angiotensin system blocking drugs described receptor antagonism as one of several points at which the cascade can be interrupted (PMID 24038019). Approved uses and monitoring are set by the label and the prescribing clinician.
How do ARBs differ from ACE inhibitors?▾
ACE inhibitors block the enzyme that converts angiotensin I to angiotensin II, while ARBs block the AT1 receptor itself. ACE also degrades bradykinin, so inhibiting it allows bradykinin to accumulate, the mechanism conventionally linked to the dry cough. ARBs do not inhibit that enzyme, so bradykinin metabolism is unchanged. A 2014 review set out these mechanistic differences (PMID 24038019).
Do ARBs lower angiotensin II levels?▾
No. The blockade is at the receptor, not at the enzyme that makes the peptide, so circulating angiotensin II is not reduced and remains available to non-AT1 receptors. A 2014 review of renin-angiotensin system blocking drugs described this distinction between enzyme inhibition and receptor antagonism when comparing the classes (PMID 24038019). Clinical meaning for any individual is a question for a prescriber.
What is aldosterone breakthrough?▾
A 2022 pharmacological review described aldosterone breakthrough as the return of aldosterone concentrations toward or above baseline during continued treatment with renin-angiotensin system inhibitors, and examined the proposed mechanisms behind it (PMID 35422512). The same review discussed aldosterone's wider roles during RAAS inhibition (PMID 35422512). This is a mechanism-level observation reported in the literature, not guidance for any reader.
What adverse effects does the literature describe for this class?▾
Labels and reviews describe symptomatic hypotension and dizziness, raised serum potassium, and changes in renal function in susceptible individuals. A 2002 review described how glomerular filtration depends on angiotensin II mediated efferent arteriolar tone (PMID 11982815), and a 2022 review discussed aldosterone's role in potassium handling during RAAS inhibition (PMID 35422512). Labels also carry a boxed warning about pregnancy.
Are ARBs studied outside blood pressure control?▾
Yes, in research settings. A 2025 scoping review assessed candesartan for migraine headache (PMID 40571531), a 2024 review examined telmisartan and metabolic syndrome components including partial PPAR-gamma activity (PMID 38228033), and a 2024 laboratory paper described a two-phase mechanism for topical losartan in corneal stromal fibrosis (PMID 38570181). None of these establishes an approved indication.
Who decides whether an ARB is used?▾
The prescribing clinician does, working from the approved label for the specific product and from the individual clinical picture. This page describes mechanism and class-level label facts only, and contains no doses, no comparisons ranking one drug above another, and no guidance on starting, stopping, switching or combining medicines. Personal questions belong with the prescriber, not with a web page.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education. It is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.